What is the impact of the signing of the Sino US trade agreement on the pharmaceutical sector?

On January 15, with the joint efforts of the economic and trade teams of China and the United States, adhering to equality and mutual respect, China and the United States formally signed the first phase of the economic and trade agreement in Washington, D.C., the capital of the United States The agreement includes nine chapters, including the preamble, intellectual property rights, technology transfer, food and agricultural products, and financial services And the U.S side promised to implement the relevant commitments of canceling the tariff increase on products to China in stages, and to realize the change of tariff increase from rise to fall It can be said that the goods are full of dry goods Among them, there are many agreements related to drugs, three of which are most noteworthy: first, the intellectual property documents related to drugs point out that drug problems are related to people's life and health, so it is still necessary to find new treatment methods and therapies, such as cancer treatment, diabetes, high blood pressure and stroke In order to promote innovation and cooperation in the pharmaceutical field and better meet the needs of patients, each party shall provide effective protection and implementation of intellectual property rights related to drugs, including patents and unpublished tests or other data submitted as conditions of marketing license PS: in terms of intellectual property rights, the rights and obligations of both parties are equal and mutually beneficial, which has a strong protective effect on the investment enterprises of both parties, especially the innovative enterprises, which is of epoch-making significance to the investment industries of both parties It is feasible to protect the intellectual property rights well, which is not only conducive to more foreign intellectual property rights and foreign capital entering China, but also conducive to the innovation and development of the pharmaceutical industry 2： The extension of valid patent period related to drugs refers to the extension of valid patent period and relevant solutions Both China and the United States are required to provide the extension of patent period to compensate for unreasonable delay during the granting of patent or drug sales approval The patent system has been in operation for more than 200 years, and the basic system has been basically improved Now, the extension of the effective patent period of drugs is only aimed at the waste of patent period caused by unreasonable delay So, for drug manufacturers, it is good news to a large extent After all, the patent period of drugs from R & D and approval to listing is almost the same, which can save time It's also a good thing 3： Specific measures related to counterfeit drugs: China and the United States should take effective and rapid law enforcement actions for counterfeit drugs and related products containing active pharmaceutical ingredients, bulk chemicals or biological substances Through the above three points, the drug-related law enforcement information and regulatory information will be synchronized in the United States, so as to facilitate the timely and effective handling of illegal drugs in the two countries, not only put out the fire of "crime" from the communication channels, but also cut off the fuse from the circulation channels, which has a strong role in resisting fake drugs and substandard drugs In addition, as far as the overall document is concerned, the agreement largely pushed the US side to realize the turning point of tariff increase to reduction, including suspending the tariff to be increased on December 15 last year, and reducing the tariff rate to 7.5% from 15% which came into effect on September 1 last year Appendix: list of additional exports of the United States to China within two years: picture source: picture source: Sino US trade agreement document picture source: Sino US trade agreement document at the same time, the results of the negotiation on the agreement show that to a large extent in the future, China's import proportion to the United States will increase significantly, and many people are worried about whether it will impact some industries in China? In fact, in the short term, the impact of expanding imports on the domestic market is positive, even affecting the production status and living space of some domestic production enterprises (especially the old enterprises with insufficient core competitiveness) But in the long term, the pharmaceutical industry has always advocated the survival of the fittest and innovative development The principle of "born in trouble and die in peace" is advocated by the state Perhaps with the introduction of advanced management concepts and mechanisms and the impact of powerful enterprises in the world, it will also bring strong external pressure to domestic enterprises, especially drug manufacturing enterprises Only when there is pressure, there will be power Effective and benign competition may force China's industry to accelerate transformation and upgrading, so as to make great progress and catch up with the world U.S.A Attachment: the full text of the Sino US trade agreement Pdf editor in charge | penicillin statement: this point of view only represents the author, does not represent the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.